Evaluates gene delivery efficiency in ocular cells using a novel nanocarrier, suggesting its potential in gene therapy.
In this study, we developed a biodegradable CS-PLGA/pEGFP/HA ternary complex for intraocular gene therapy via intravitreal injection. In our system, plasmid-enhanced green fluorescent protein (pEGFP) was chosen as the model plasmid, chitosan (CS) was used to condense the plasmid DNA, poly(lactic-co-glycolic acid) (PLGA) provided sustained-release potential and structural protection for plasmids, and hyaluronic acid (HA) served as a ligand for targeting CD44 receptors on the surface of adult retinal pigment epithelial (ARPE-19) cells. In vitro evaluations revealed that the CS-PLGA/pEGFP/HA group exhibited higher cellular uptake, transfection efficiency, and protein expression levels compared with those of free pEGFP and CS-PLGA/pEGFP groups. Several previous studies have verified the feasibility of intravitreal plasmid delivery. Therefore, this CS-PLGA/pEGFP/HA ternary complex is a promising nonviral vector with the potential to deliver plasmids to ocular tissues and enhance protein expression in target cells.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: